Global Combination Antibody Therapy Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Combination Antibody Therapy Market Research Report 2024
Antibody, also called immunoglobulin, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto antigens in order to remove them from the body. A wide range of substances are regarded by the body as antigens, including disease-causing organisms and toxic materials such as insect venom.
Treatment that uses antibodies to help the body fight cancer, infection, or other diseases. Antibodies are proteins made by the immune system that bind to specific markers on cells or tissues. IgG1 antibodies are a type of antibody made in the laboratory that can be used in diagnosis or treatment. In cancer treatment, IgG1 antibodies may kill cancer cells directly, they may block development of tumor blood vessels, or they may help the immune system kill cancer cells.
According to MRAResearch’s new survey, global Combination Antibody Therapy market is projected to reach US$ 63730 million in 2033, increasing from US$ 36080 million in 2022, with the CAGR of 8.0% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Combination Antibody Therapy market research.
The industry's leading producers are Roche, Abbvie and J & J, with revenues of 15.61%, 12.10% and 10.05% in 2019.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Combination Antibody Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Biogen
Roche Holdings
Seattle Genetics
Amgen
Bristol-Myers Squibb
Eli Lilly
Novartis
Sanofi
Celgene
Genmab
Segment by Type
Chemotherapy Antibody
Antibody
Conjugated Antibodies
Bispecific Antibodies
Hospitals
Cancer Research Institutes
Clinics
ASCs
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Combination Antibody Therapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Treatment that uses antibodies to help the body fight cancer, infection, or other diseases. Antibodies are proteins made by the immune system that bind to specific markers on cells or tissues. IgG1 antibodies are a type of antibody made in the laboratory that can be used in diagnosis or treatment. In cancer treatment, IgG1 antibodies may kill cancer cells directly, they may block development of tumor blood vessels, or they may help the immune system kill cancer cells.
According to MRAResearch’s new survey, global Combination Antibody Therapy market is projected to reach US$ 63730 million in 2033, increasing from US$ 36080 million in 2022, with the CAGR of 8.0% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Combination Antibody Therapy market research.
The industry's leading producers are Roche, Abbvie and J & J, with revenues of 15.61%, 12.10% and 10.05% in 2019.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Combination Antibody Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Biogen
Roche Holdings
Seattle Genetics
Amgen
Bristol-Myers Squibb
Eli Lilly
Novartis
Sanofi
Celgene
Genmab
Segment by Type
Chemotherapy Antibody
Antibody
Conjugated Antibodies
Bispecific Antibodies
Segment by Application
Hospitals
Cancer Research Institutes
Clinics
ASCs
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Combination Antibody Therapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source